cas 62595-74-8|| where to buy 3-Bromopiperidine-2,6-dione

Nom du produit:3-Bromopiperidine-2,6-dione

IUPAC Name:3-bromopiperidine-2,6-dione

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM143204-25g	in stock	ȎǊĽ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 62595-74-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:62595-74-8; Formule moléculaire:C5H6BrNO2; Point de fusion:-; Code SMILES:O=C(C(Br)CC1)NC1=O; Densité:1.748g/cm3

: Numéro de catalogue:CM143204; Poids moléculaire:192.01; Point d'ébullition:336.4°C at 760 mmHg; N° Mdl:MFCD11053059; Stockage:Keep in a tight container and store at 2°C~8°C

: Piperidines; Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.; Piperidine,Piperidine Price; if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

: KT-474; Kymera announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa (HS) evaluating KT-474 (SAR444656). The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS. Kymera's partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD. Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflammatory diseases where there is an opportunity to significantly advance the standard of care, including HS and AD. Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

: CFT7455; C4 Therapeutics recently announces positive results from initial study of CFT7455 in Relapsed/Refractory Multiple Myeloma (R/R MM). CFT7455 is a potent, selective MonoDAC (Monofunctional Degradation Activating Compound) degrader of IKZF1/3 gene. It binds to cereblon (CRBN) E3 ligase with high affinity in Multiple Myeloma and Non-Hodgkin Lymphoma. CFT7455 can act as a single agent or in combination with Dexamethasone for R/R MM patients.